Raum S, Verla-Pharm Arzneimittel, 82324 Tutzing, DE

Background/objectives. The symptoms of magnesium deficiency and fibromyalgia syndrome (FMS) overlap considerably. The data on magnesium status in FMS or its influence on FMS symptoms is limited and heterogeneous. Therefore, the aim of this study was to record the magnesium status of FMS patients and possible correlations of magnesium status with the severity and symptoms of FMS.

Methods. In 100 FMS patients, the magnesium concentrations in serum, whole blood and erythrocytes as well as the ionised magnesium in serum were measured and the respective ratio to calcium was calculated. The severity and symptoms of FMS were recorded using validated questionnaires: ACR criteria (American College of Rheumatology), Fibromyalgia Impact Questionnaire (FIQ-G), patient health questionnaires (PHQ-15, PHQ-4).

Results. Based on a conventional reference range for magnesium (serum: 0.76-1.10 mmol/l), no magnesium deficiency could be detected. However, using more current guiding values/target criteria (serum magnesium ≥ 0.85 mmol/l; magnesium-calcium quotient in serum > 0.4), a prevalence of magnesium deficiency of 20.2% and 83.8%, respectively, was recorded. There were no clear correlations of magnesium status with severity and symptoms of FMS.

Discussion/conclusions. The presence of magnesium deficiency in FMS could not be confirmed with certainty, but current parameters indicate a high proportion of FMS patients with latent magnesium deficiency. Due to general considerations and in view of the similar symptoms, a magnesium deficit in these patients should be avoided or treated in order not to unnecessarily aggravate their complaints.